Effect of a combination of telmisartan and amlodipine in hypertensive dogs

Systemic hypertension (SHT) in dogs is considered a health risk factor. Telmisartan is a well-known antihypertensive agent in humans. There are limited reports about its efficacy in dogs. Five dogs with primary and secondary SHT refractory to the combined treatment of benazepril and amlodipine had a...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary record case reports 2018-09, Vol.6 (2), p.n/a
Main Authors: Caro-Vadillo, Alicia, Daza-González, Maria Angeles, Gonzalez-Alonso-Alegre, Elisa, Rodríguez, Alfonso, Gómez-García, José
Format: Article
Language:English
Subjects:
Blood pressure
Case reports
Diuretics
Dogs
Drug dosages
Hypertension
Kidney diseases
Potassium
systemic hypertension
systolic blood pressure
telmisartan
Veterinary medicine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic hypertension (SHT) in dogs is considered a health risk factor. Telmisartan is a well-known antihypertensive agent in humans. There are limited reports about its efficacy in dogs. Five dogs with primary and secondary SHT refractory to the combined treatment of benazepril and amlodipine had a successful control of systolic arterial blood pressure (SBP) when telmisartan was combined with amlodipine. SBP showed a significant reduction after any treatment, but only reached successful control when amlodipine plus telmisartan was administered (median SBP: 215 mmHg before treatment [min-max: 180–240 mmHg]; 180 mmHg for amlodipine plus benazepril treatment [min-max: 170–210 mmHg]; 142 mmHg after amlodipine plus telmisartan treatment [min-max: 120–165 mmHg]). This control remained stable in the long-term follow-up (average 5.2 months). In the cases reported, the telmisartan plus amlodipine treatment showed good efficacy in the control of SHT, regardless of cause, and was well tolerated in all patients.
ISSN:2052-6121
2052-6121
DOI:10.1136/vetreccr-2017-000471